These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25238116)

  • 21. Assessment methods of inhaled aerosols: technical aspects and applications.
    Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
    Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM; Kanfer I; Tsang YC; Cardot JM
    AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.
    Hochhaus G; Davis-Cutting C; Oliver M; Lee SL; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1305-11. PubMed ID: 26033698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
    Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
    Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
    Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
    Eur J Pharm Sci; 2011 Nov; 44(4):506-13. PubMed ID: 21946259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro/in vivo comparisons in pulmonary drug delivery.
    Newman SP; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):77-84. PubMed ID: 18518834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Generic drugs: quality, efficacy, safety and interchangeability].
    Tschabitscher D; Platzer P; Baumgärtel C; Müllner M
    Wien Klin Wochenschr; 2008; 120(3-4):63-9. PubMed ID: 18322766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of Brazilian Requirements for Therapeutic Equivalence of Orally Inhaled and Nasal Drug Products.
    Silva MC; Costa HS; Valadares BN; Grecchi L; Nagao L; Santos GML
    AAPS PharmSciTech; 2019 Jun; 20(6):235. PubMed ID: 31236849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric in vitro and in silico models of deposition via oral and nasal inhalation.
    Carrigy NB; Ruzycki CA; Golshahi L; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):149-69. PubMed ID: 24870701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA mulls changes to bioequivalence standards.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205
    [No Abstract]   [Full Text] [Related]  

  • 32. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmarketing in vitro/in vivo assessment of fixed dose combination products of first line antiretrovirals.
    Joshi A; Esseku F; Silva L; Igwilo C; Oqua D; Kunle B; Obodozie O; Inyang U; Adeyeye MC
    J Pharm Sci; 2010 Jun; 99(6):2655-63. PubMed ID: 20054854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report.
    O'Connor D; Adams WP; Chen ML; Daley-Yates P; Davis J; Derendorf H; Ducharme MP; Fuglsang A; Herrle M; Hochhaus G; Holmes SM; Lee SL; Li BV; Lyapustina S; Newman S; Oliver M; Patterson B; Peart J; Poochikian G; Roy P; Shah T; Singh GJ; Sharp SS
    J Aerosol Med Pulm Drug Deliv; 2011 Jun; 24(3):119-35. PubMed ID: 21453049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system.
    Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
    Eur J Pharm Sci; 2018 Sep; 122():264-272. PubMed ID: 29981406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.
    Lin Z; Zhou D; Hoag S; Qiu Y
    AAPS J; 2016 Mar; 18(2):333-45. PubMed ID: 26769249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling and simulation of biopharmaceutical performance.
    Zhang X; Lionberger RA
    Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence requirements in the European Union: critical discussion.
    García-Arieta A; Gordon J
    AAPS J; 2012 Dec; 14(4):738-48. PubMed ID: 22826032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.
    Davit B; Braddy AC; Conner DP; Yu LX
    AAPS J; 2013 Oct; 15(4):974-90. PubMed ID: 23821352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.